Artificial Pancreas Market Industry CAR T CELL THERAPY MARKET - GLOBAL INDUSTRY INSIGHTS, TRENDS AND OPPORTUNITY ANALYSIS, 2016-2024 [DATE] [COMPANY NAME] [Company address] Report Description Immunotherapy has been the buzzword for cancer treatment over the last few years. With long impending clinical trials and research activities carried out with chimeric antigen receptor cells (CAR-T) cells, pharmaceutical giants are expected to launch in 2017 and commercialize the product in next 2 to 3 years. The idea behind introducing CAR-T cells is to attack cancer cells – thereby achieving higher treatment success rate. It involves adoptive cell transfer: extraction, expansion and modification of patient’s T-cell and then transferring back to patient’s body system. Sales of CAR T-cell therapy product is expected to grow at double digit growth rate wherein a major chunk of the market will be captured by players engaged in this industry. Market Dynamics Once in the market, it will be a lifesaving drug for over 30 million population creating huge market opportunities for the players. Moreover, it is expected to treat over 80% of children diagnosed with acute lymphoblastic leukemia (ALL) in B cells. Leukemia patients are expected to receive a great sigh of relief with introduction of such living drug. According to U.S. National Cancer Institute, over 339 thousand U.S. population is currently suffering Leukemia with 1.5 percent of population expected to detect leukemia once in lifespan. Growing prevalence rate and demand for effective treatment modalities is expected to create new market opportunities for the players. View the full Report @ https://www.coherentmarketinsights.com/ongoing-insight/car-t-celltherapy-market-global-industry-insights-trends-outlook-and-opportunity-analysis-2016-2024-1 Market in few years will be highly consolidated with only 3 players ruling the market however, with this is not only expected to benefit manufacturers but also pharmacies and hospitals and patients across value chain. Though the industry is expected to cater to millions of consumer over the forecast period, failing clinical trials, low success rate towards solid tumors and cost structure in scaling up personalized medici nes towards high cost to return profits are major challenges being faced by the companies. CAR-T cell personalized treatment cell might require change in capacity of bioreactors of around 5 thousand liters. Moreover, it will require companies to train staff incurring additional cost at early years. Production is expected to jump by 2020. Regional Analysis North America and Europe are expected to dominate the overall CAR T cells market throughout the forecast period. The regions are early adopters of newly developed technology. Moreover, demand is expected to be further propelled by large consumer base. As per the estimates, the region spend over 10% of their gross income on healthcare issues which is predominately higher among aging population. With over 80% of personalized medicine market captured by North America and Europe, the CAR T Cell therapy is expected to achieve significant sales in these regions. Moreover, increasing popularity of personalized medicines will further propel the demand for CAR-T cell products in the regions. Ask for Free TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1 Asia Pacific is a lucrative market for companies engaged in CAR-T cell therapy. However, commercialization is not expected to take place in early years. Market in Asia Pacific is expected to grow at relatively sluggish rate between 2017 and 2022. Japan will be the key market in Asia Pacific for the players in early years. However, low consumer base and low prevalence rate of cancer compared to developed region will lead to moderate growth opportunities in near future. Company Analysis Juno Therapeutics, Kite and Novartis are currently engaged in CAR-T cell therapeutic products – commercialization of same is expected to start from 2017. Kite is looking forward to FDA approval for its KTE-C19. The clinical trial is carried out with National Cancer Institute. Judo’s JCAR015 is in phase II for ALL. Whereas Novartis sees market opportunity with CAR T Cell therapy, CTL019. With high remission rates, the product is expected to create exponential market opportunities for the players. About Us COMPANY OVERVIEW Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. Our global team of over 100 research analysts and freelance consultants provide market intelligence from the very molecular country level and also provide a global perspective of the market. Our team is of the most vital cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive defusion training module.This allows for an objective and unbiased assessment of the market. We pride ourselves in my constantly striving to update our extremely in-depth understanding of the market by closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth path in the future. Contact Us CORPORATE OFFICE: Coherent Market Insights 303, Astral Court,Above Reliance Fresh, Near Gaikwad Petrol Pump, Aundh, Pune – 411045, India [email protected]
Juno Therapeutics, Kite and Novartis are currently engaged in CAR-T cell therapeutic products – commercialization of same is expected to start from 2017. Kite is looking forward to FDA approval for its KTE-C19. The clinical trial is carried out with National Cancer Institute. Judo’s JCAR015 is in phase II for ALL. Whereas Novartis sees market opportunity with CAR T Cell therapy, CTL019. With high remission rates, the product is expected to create exponential market opportunities for the players.
© Copyright 2024 Paperzz
